69 Views | 32 Downloads
Alberto Albanese, alberto.albanese@humanitas.it; Tel.: +39-02-8224-6418
Conceptualization, M.A., G.C., A.S. and M.V.; validation, A.A., J.W., W.H.J., A.C. and H.A.J.; formal analysis, G.C.; resources, M.V.; writing—review and editing, A.A., J.W., W.H.J., A.C., M.A., G.C., A.S., M.V. and H.A.J. All authors have read and agreed to the published version of the manuscript.
The authors wish to acknowledge Deirdre Elmhirst and Gill Gummer (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript, funded by Merz Therapeutics.
Alberto Albanese has received grants/research support from Boston Scientific and honoraria/consultation fees from Merz Therapeutics and Ipsen. Jörg Wissel has served as an investigator/speaker for AbbVie/Allergan, Ipsen, Medtronic, and Merz, and as an advisor/consultant for AbbVie/Allergan, Ipsen, Medtronic, and Merz. Wolfgang H. Jost is an advisor and speaker for Merz Therapeutics, AbbVie, and Ipsen. Anna Castagna has received speaker honoraria from Merz Therapeutics and Ipsen. Michael Althaus, Georg Comes, Astrid Scheschonka, and Matteo Vacchelli are employees of Merz Therapeutics GmbH. Hyder A. Jinnah has grant support (recent, active, or pending) from the US government (National Institutes of Health [NIH]) and industry (AbbVie, Addex, Aeon, Revance, Sage, and Jazz). He has also served on advisory boards or as a consultant for Addex, AbbVie Apello, CoA Therapeutics, Cavion, Daiichi Sankyo, Ipsen, Jazz, PureTech, Retrophin, Revance, and Takaha/Ene. He has received honoraria or stipends for lectures or administrative work from the International Parkinson′s Disease and Movement Disorders Society. He has also served on scientific advisory boards of several private foundations, including the Benign Essential Blepharospasm Research Foundation, the Dystonia Medical Research Foundation, and the Tourette Association of America. He is also principal investigator for the Dystonia Coalition, which has received most of its support through the NIH (grants NS116025 and NS065701 from the National Institutes of Neurological Disorders and Stroke TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences). The Dystonia Coalition has received additional material or administrative support from industry sponsors (Allergan Inc. and Merz Therapeutics) as well as private foundations (the Benign Essential Blepharospasm Foundation, Cure Dystonia [now, the Dystonia Medical Research Foundation], the National Spasmodic Dysphonia Association, and the National Spasmodic Torticollis Association).
This research was funded by Merz Therapeutics GmbH.
© 2023 by the authors.